Who Paid My Doc
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlle
Research payments
$6,167,072
Through program year 2025, $6,167,072 in research payments was reported against A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlle, across 780 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $2,600,958 | 427 |
| 2024 | Research | $3,459,702 | 328 |
| 2023 | Research | $106,413 | 25 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Mohammad Bolouri Matthews, NC Named on 164 payments
- Paayal Patel Stuart, FL Named on 66 payments
- Jeffrey Norton The Villages, FL Named on 57 payments
- Concetta Forchetti Hoffman Estates, IL Named on 57 payments
- Linda Pao Lake Worth, FL Named on 33 payments
- Shishuka Malhotra North Canton, OH Named on 33 payments
- Ramon Leon South Miami, FL Named on 32 payments
- Sheila Baez-Torres Maitland, FL Named on 27 payments
- Marshall Nash Eastpoint, FL Named on 22 payments
- Sanjiv Sharma Bakersfield, CA Named on 22 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.